Malignant melanoma is a very aggressive skin cancer, characterized by a heterogeneous
nature and high metastatic potential. The incidence of melanoma is continuously increasing …

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths and
represents a substantial disease burden worldwide. Immune checkpoint inhibitors combined …

Background Tumor microenvironment (TME) characteristics are potential biomarkers of
response to immune checkpoint inhibitors in metastatic melanoma. This study developed a …

While the tumor immune microenvironment (TIME) of metastatic melanoma has been well
characterized, the primary melanoma TIME is comparatively poorly understood. Additionally …

Simple Summary Bright-field (BF) immunohistochemistry (IHC) remains the gold standard for
histopathological evaluations. The development of new BF multiplex IHC could be very …

The biological underpinnings of therapeutic resistance to immune checkpoint inhibitors (ICI)
in adolescent and young adult (AYA) melanoma patients are incompletely understood. Here …

Programmed death-1 is a protein found on the surface of immune cells that can interact with
its ligand, programmed death-ligand 1 (PD-L1), which is expressed on the plasma …

The approval of immunotherapy for stage II-IV melanoma has underscored the need for
improved immune-based predictive and prognostic biomarkers. For resectable stage II-III …

Immunotherapies targeting the programmed cell death 1 (PD-1) and cytotoxic T-lymphocyte
antigen 4 (CTLA-4) checkpoint receptors have revolutionized the treatment of metastatic …

We present a rigorous validation strategy to evaluate the performance of Ultivue multiplex
immunofluorescence panels. We have quantified the accuracy and precision of four different …